Pharming Group N.V. has grown revenue 22% a year over three years and 12% a year over five, with earnings per share compounding at −41%. Revenue growth, 3-year annual rate: +22% (Biotechnology median +17%). Revenue growth, 5-year rate: +12%, growth has picked up over the last three years. Earnings per share, 3-year rate: −41%, earnings lagged revenue: the growth is costing something. Years of annual history on file: 8, FY2018 to FY2025, as filed.

PHARPharming Group N.V.

Healthcare

$9.70-34% 1Y

$9.70

$9.7052 weeks$21.18

Is it growing?

Mixed

Neither accelerating nor breaking down: revenue growing +27% year on year, but earnings down −122% year on year.

1 good, 1 to watch, 1 neutral

Revenue trend+27% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +12% a year.

Earnings trend−122% in a year

Trailing-twelve-month earnings per share against a year earlier. Growing slower than revenue, so the growth is costing something.

Margin direction+0.1 points operating

Trailing-twelve-month operating margin, 6.9% now against 6.8% a year earlier.

All from SEC EDGAR, as of Dec 31, 2025.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is PHAR growing?

Pharming Group N.V. has grown revenue 22% a year over three years and 12% a year over five, with earnings per share compounding at −41%.

+22%

Revenue growth, 3-year annual rate · Biotechnology median +17% · compounding fast · compounded from fiscal years as filed

Revenue growth, 5-year rate: +12%
Revenue growth, 5-year rate · +22% over three · growth has picked up over the last three years
Earnings per share, 3-year rate: −41%
Earnings per share, 3-year rate · revenue +22% · earnings lagged revenue: the growth is costing something
Years of annual history on file: 8
Years of annual history on file · FY2018 to FY2025, as filed